Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Kyung Won | - |
dc.contributor.author | Kim, Eun-Joo | - |
dc.contributor.author | Han, Hyun Jeong | - |
dc.contributor.author | Shim, Yong S. | - |
dc.contributor.author | Kwon, Jae C. | - |
dc.contributor.author | Ku, Bon D. | - |
dc.contributor.author | Park, Kee Hyung | - |
dc.contributor.author | Yi, Hyon-Ah | - |
dc.contributor.author | Kim, Kwang K. | - |
dc.contributor.author | Yang, Dong Won | - |
dc.contributor.author | Lee, Ho-Won | - |
dc.contributor.author | Kang, Heeyoung | - |
dc.contributor.author | Kwon, Oh Dae | - |
dc.contributor.author | Kim, SangYun | - |
dc.contributor.author | Lee, Jae-Hyeok | - |
dc.contributor.author | Chung, Eun Joo | - |
dc.contributor.author | Park, Sang-Won | - |
dc.contributor.author | Park, Mee Young | - |
dc.contributor.author | Yoon, Bora | - |
dc.contributor.author | Kim, Byeong C. | - |
dc.contributor.author | Seo, Sang Won | - |
dc.contributor.author | Choi, Seong Hye | - |
dc.date.available | 2020-02-27T17:43:38Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2017-08-07 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/5822 | - |
dc.description.abstract | Background and objective Studies investigating the impact of white matter hyperintensities (WMHs) on the response of acetylcholinesterase inhibitors in patients with Alzheimer's disease (AD) have presented inconsistent results. We aimed to compare the effects of the rivastigmine patch between patients with AD with minimal WMHs and those with moderate WMHs. Methods Three hundred patients with mild to moderate AD were enrolled in this multicenter prospective open-label study and divided into two groups. Group 1 comprised patients with AD with minimal WMHs and group 2 comprised those with moderate WMHs. The patients were treated with a rivastigmine patch for 24 weeks. Efficacy measures were obtained at baseline and after 24 weeks. The primary endpoint was the change in the AD Assessment Scale-Cognitive subscale (ADAS-Cog) from the baseline to the end of the study. Results Of the 300 patients, there were 206 patients in group 1 and 94 patients in group 2. The intention-to-treat group comprised 198 patients (group 1, n = 136; group 2, n = 46) during the 24-week study period. Demographic factors did not differ between group 1 and group 2. There were no significant differences in change in ADAS-cog between group 1 (-0.62 +/- 5.70) and group 2 (-0.23 +/- 5.98) after the 24-week rivastigmine patch therapy (p = 0.378). The patients in group 1 had a 0.63-point improvement from baseline on the Frontal Assessment Battery, while group 2 had a 0.16-point decline compared to baseline at the end of the study (p = 0.037). The rates of adverse events (AEs) (42.6 vs. 40.3%) and discontinuation due to AEs (10.3% vs. 4.3%) did not differ between the groups. Conclusions Although the efficacy and tolerability of rivastigmine patch therapy were not associated with WMH severity in patients with AD, some improvement in frontal function was observed in those with minimal WMHs. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | PUBLIC LIBRARY SCIENCE | - |
dc.relation.isPartOf | PLOS ONE | - |
dc.subject | SUBCORTICAL VASCULAR DEMENTIA | - |
dc.subject | ACETYLCHOLINESTERASE INHIBITOR ENA-713 | - |
dc.subject | PLACEBO-CONTROLLED TRIAL | - |
dc.subject | CEREBRAL BLOOD-FLOW | - |
dc.subject | RISK-FACTORS | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | CHOLINESTERASE-INHIBITORS | - |
dc.subject | CHOLINERGIC PATHWAYS | - |
dc.subject | DISEASE | - |
dc.subject | BRAIN | - |
dc.title | Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000406998800014 | - |
dc.identifier.doi | 10.1371/journal.pone.0182123 | - |
dc.identifier.bibliographicCitation | PLOS ONE, v.12, no.8 | - |
dc.identifier.scopusid | 2-s2.0-85026872237 | - |
dc.citation.title | PLOS ONE | - |
dc.citation.volume | 12 | - |
dc.citation.number | 8 | - |
dc.contributor.affiliatedAuthor | Park, Kee Hyung | - |
dc.type.docType | Review | - |
dc.subject.keywordPlus | SUBCORTICAL VASCULAR DEMENTIA | - |
dc.subject.keywordPlus | ACETYLCHOLINESTERASE INHIBITOR ENA-713 | - |
dc.subject.keywordPlus | PLACEBO-CONTROLLED TRIAL | - |
dc.subject.keywordPlus | CEREBRAL BLOOD-FLOW | - |
dc.subject.keywordPlus | RISK-FACTORS | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | CHOLINESTERASE-INHIBITORS | - |
dc.subject.keywordPlus | CHOLINERGIC PATHWAYS | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | BRAIN | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.